Morning Industry Symposium: CDK4/6 inhibitors in advanced breast cancer: The future is now
Supported by Pfizer
Friday, October 12, 2018
07:00-08:30
Breakfast will be served prior to the session
| Chairpersons | Arlene Chan, Australia Catherine Oakman, Australia |
Hall B |
| 07:15 – 07:45 | The science behind CDK4/6 inhibition Javier Cortes, Spain |
|
| 07:45 – 08:15 07:45 07:55 08:05 |
DEBATE: That all 1st line stage 4 ER+/HER2-patients should have a CDK4/6 inhibitor Yes: Rebecca Dent, Singapore No: Nick Murray, Australia Discussion |
|
| 08:15 – 08:30 | Discussion | |